GSA Capital Partners LLP Increases Stake in ImmunityBio, Inc. (NASDAQ:IBRX)

GSA Capital Partners LLP lifted its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 290.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 107,985 shares of the company’s stock after acquiring an additional 80,318 shares during the period. GSA Capital Partners LLP’s holdings in ImmunityBio were worth $402,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Lazard Asset Management LLC grew its position in ImmunityBio by 102.6% in the first quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock valued at $68,000 after acquiring an additional 6,593 shares in the last quarter. Axxcess Wealth Management LLC purchased a new position in shares of ImmunityBio during the 1st quarter valued at approximately $85,000. Algert Global LLC purchased a new position in shares of ImmunityBio during the 2nd quarter valued at approximately $86,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after buying an additional 4,545 shares during the last quarter. Finally, Simplicity Wealth LLC boosted its stake in shares of ImmunityBio by 46.0% during the 2nd quarter. Simplicity Wealth LLC now owns 15,806 shares of the company’s stock valued at $100,000 after buying an additional 4,983 shares during the last quarter. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IBRX has been the topic of a number of research reports. Piper Sandler dropped their target price on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a report on Monday, August 19th. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Trading Up 4.5 %

IBRX stock opened at $5.10 on Friday. The firm has a 50-day moving average of $4.24 and a two-hundred day moving average of $5.21. The firm has a market capitalization of $3.55 billion, a PE ratio of -5.54 and a beta of 0.99. ImmunityBio, Inc. has a one year low of $3.10 and a one year high of $10.53.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.